Immunic Inc IMUX

NAS: IMUX | ISIN: US4525EP1011 14/11/2024

1,090 USD (-6,84%)

(-6,84%) 14/11/2024

Grafiek Immunic Inc

Grafiek Immunic Inc

1 dag1d -6,84%
1 week1w -7,63%
1 maand1m -27,33%
3 maanden3m -19,26%
6 maanden6m -15,83%
1 jaar1j 9,00%
5 jaar5j -86,17%

Immunic Inc in het nieuws

Toon enkel gratis nieuws

4 september 2024 · Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome · Persbericht

28 augustus 2024 · Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September · Persbericht

8 augustus 2024 · Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

1 augustus 2024 · Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update · Persbericht

24 juli 2024 · Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec · Persbericht

9 juli 2024 · Immunic Appoints Jason Tardio as Chief Operating Officer and President · Persbericht

28 mei 2024 · Immunic to Participate in Industry and Scientific Conferences in June · Persbericht

8 mei 2024 · Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

6 mei 2024 · Immunic to Participate in Investor and Scientific Conferences in May · Persbericht

1 mei 2024 · Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update · Persbericht

Profiel Immunic Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

CEO: Daniel Vitt

Werknemers: 58

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe